Are Peptides Safe? Approved, Compounded and Research-Use-Only Compared

Some peptides are well-studied drugs with known risks, and many of the ones sold online have never been tested for safety in people at all. An FDA-approved peptide such as semaglutide comes with a label that lists its risks from large trials, including a boxed warning.^[2] A compounded peptide is made by a pharmacy and is not FDA-approved, so FDA has not reviewed its safety or quality.^[1] A “research use only” vial sits outside both systems, and laboratories that have tested products like it found the wrong amount of drug, bacterial endotoxin, heavy metals and, in some cases, a different peptide from the one on the label.^[6][7][9] So the safety question has three answers, and which one applies depends on what is in the vial and who made it.

Safety by kind of product

Approved peptide drugs: real risks, written down

The peptides with the strongest safety records are the approved ones, because their makers had to run trials and report what happened. That does not make them risk-free. Wegovy’s label opens with a boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether it does so in people, so people whose family has had medullary thyroid cancer, or who have had it themselves, should not take it.^[2] The point is that the risks are known, measured and printed, so a prescriber can weigh them. Our list of FDA-approved peptides covers the GLP-1 drugs and the others people ask about.

Approved peptides cause harm mostly when they are used outside the system that makes them safe: counterfeit pens, unapproved salt forms, or doses measured by hand from a vial. FDA has received reports of adverse events, some needing hospital care, from patients and clinicians who measured the wrong dose of compounded semaglutide.^[3]

Compounded peptides: not reviewed, and underreported

A compounded peptide is made by a licensed pharmacy for a named patient. HHS’s own policy says it plainly: compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are sold.^[1] The best numbers on what goes wrong come from the compounded GLP-1 drugs, because so many people used them. By May 31, 2026, FDA’s count stood at 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide.^[3] FDA warns that the real numbers are likely higher, because federal law does not require a 503A pharmacy to send adverse events to FDA.^[3]

For the peptides with no approved version, the record is thinner. When FDA reviewed BPC-157 for the compounding list in 2026, its adverse-event database held three reports through December 4, 2025, and FDA noted that 503A compounders generally do not report.^[5] Those three cases are covered in BPC-157 side effects. A small number of reports does not mean a peptide is safe. It mostly reflects how few people report and how little anyone has looked.

Since October 28, 2026, HHS has said it does not intend to take enforcement action against 503A pharmacies that compound six peptides (BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c) if every condition of its interim policy is met.^[1] Several conditions are safety measures: each batch of raw peptide must come from an FDA-registered facility with a certificate of analysis covering identity, purity, potency, endotoxins, heavy metals, microbes and impurities; products may contain only one active ingredient; and pharmacies must report serious adverse events to FDA’s MedWatch program.^[1] HHS said it may revisit the policy if a safety signal or quality problem appears.^[1] The policy does not cover 503B outsourcing facilities.^[14] The HHS peptide compounding policy explainer lists all ten conditions.

Research-use-only peptides: what testing has found

A vial carrying a research-only or not-for-human-use label is made with no prescription, no pharmacy and no regulator checking the batch. FDA has told sellers that the label does not change what the product is when the website shows it is meant for people.^[10] HHS gave the same products as its reason for acting: the policy is meant to discourage use of research-use-only peptides from foreign manufacturers that, in its words, pose a safety risk to US patients.^[1] The legal side is set out in research-use-only vs compounded peptides.

When laboratories buy these products and test them, the results are poor:

• Wrong amounts and endotoxin. Researchers bought semaglutide vials from illegal online pharmacies. The vials held 28.56% to 38.69% more semaglutide than the label said, the powder was only 7.7% to 14.37% semaglutide by weight against a claimed 99% purity, and endotoxin, a fever-causing residue of bacteria, was found in every sample.^[7]
• Heavy metals. A Belgian study of the ten falsified peptide drugs most often found on that market, bought from three suspect websites, found purity as low as 5% for some peptides and arsenic and lead in samples, several of them up to ten times the international safety limit for injectable drugs.^[6]
• A different peptide. Of 17 black-market products sold as follistatin, only nine contained follistatin, and some of the others contained growth-promoting peptides instead.^[9] Doping-control chemists have also found modified versions of GHRP-2, GHRP-6 and ipamorelin with an extra amino acid in black-market products.^[8]

A certificate of analysis from the seller does not settle the question. FDA noted that the certificate submitted with the BPC-157 nomination did not mention an endotoxin test, which it calls a critical quality check for anything injected.^[5] What each line on a certificate can and cannot prove is explained in how to read a peptide certificate of analysis.

The risks FDA has named for unapproved peptides

In 2023 FDA placed many popular peptides in Category 2, the group of compounding ingredients it flags as possibly carrying serious safety risks. Most of those nominations were later withdrawn, but FDA’s page still records the concern it had about each one.^[4] The concern that recurs is immunogenicity: an injected peptide, especially one with impurities or clumped molecules, can provoke an immune reaction against itself or the body’s own proteins. For most of the list, FDA says it lacks the information to know whether the peptide would harm people at all.^[4]

Two broader risks apply to anything injected outside the medical system. An injection bypasses the body’s first defenses, so contamination can lead to serious infection, including sepsis.^[11] And people who use these products often combine several of them, which makes it hard to tell which one caused a problem.^[13] Clinical reviews in 2026 list contamination, manufacturing impurities and inaccurate dosing among the main hazards of unregulated peptides, alongside the unknown long-term effects of signaling molecules that affect growth and blood vessels.^[12][13]

How to judge whether a peptide product is safe to consider

• Is it approved? If the peptide is an FDA-approved drug, the label lists its risks and a prescriber can weigh them. If it is not, nobody has shown it is safe at any dose.
• Who made it? A licensed pharmacy filling a prescription for you is accountable to a state board. A research-chemical website is accountable to no one for what is in the vial.
• Is it one ingredient? Blends make side effects impossible to trace, which is why the HHS policy covers single-ingredient products only.^[1]
• What human data exist? For many popular peptides the answer is none, or a few people in uncontrolled reports. Our peptide status checker shows each peptide’s regulatory status.
• Can a problem be reported? Report any reaction to a compounded or unapproved product to FDA’s MedWatch program, whoever sold it.